FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2026522667> ?p ?o ?g. }

• W2026522667 endingPage "644" @default.
• W2026522667 startingPage "636" @default.
• W2026522667 abstract "Antimuscarinic compounds are increasingly used to treat the symptoms of overactive bladder; however, their use is often restricted by peripheral adverse effects (AEs). On the other hand, data regarding their influence on the central nervous system (CNS) are limited. This randomized, single-blind, parallel-group quantitative-topographical EEG (qEEG) study of clinical phase I investigates the potential CNS adverse effects of the three antimuscarinic drugs--tolterodine, oxybutynin, and trospium chloride--in comparison to placebo. Overall, 4 x 16 (total 64) young, healthy male volunteers were included in the study. The subjects were given either placebo or the clinically recommended daily doses of the drugs dispensed in three doses on a single day (tolterodine 2 mg bid and once placebo, total 4 mg/d; oxybutynin 5 mg tid, total 15 mg/d; and trospium chloride 15 mg tid, total 45 mg/d). The qEEG was recorded prior to and up to 4 hours after each intake of the trial medication (a total of 10 qEEG sessions) under three different conditions: at rest with eyes open, eyes closed, and under mental demand. The drug tolerability was subjectively evaluated by the volunteer and the investigator. In comparison to placebo (10% confidence interval), tolterodine and trospium chloride did not induce changes of the qEEG power in five of the six frequency bands (i.e., delta, alpha 1, alpha 2, beta 1, and beta 2). Isolated power decreases were only observed in the theta frequency band. In contrast, oxybutynin caused significant power reductions in four frequency bands (theta, alpha 1, alpha 2, and beta 1; p < 0.01). The subjectively evaluated drug tolerability was comparable between all treatment groups, although differences in the AE occurrence existed, with the AE frequency being higher in the oxybutynin group. The results of this study support the findings that oxybutynin as a tertiary amine crosses the blood-brain barrier, causing significant qEEG activity changes and more pronounced central adverse effects. Although tolterodine is also a tertiary amine, it shows limited effects on qEEG activity (i.e., slight theta power reductions), comparable to the effects of trospium chloride, a quarternary amine, which barely crosses the blood-brain barrier. The minimal qEEG changes observed with tolterodine and trospium chloride reflect most probably a rebound message from the peripheral target organs. Prescription of oxybutynin thus implicates a higher risk of CNS side effects." @default.
• W2026522667 created "2016-06-24" @default.
• W2026522667 creator A5037226126 @default.
• W2026522667 creator A5049912941 @default.
• W2026522667 creator A5084392741 @default.
• W2026522667 date "2001-06-01" @default.
• W2026522667 modified "2023-10-18" @default.
• W2026522667 title "Effects of Tolterodine, Trospium Chloride, and Oxybutynin on the Central Nervous System" @default.
• W2026522667 cites W101953095 @default.
• W2026522667 cites W1965390983 @default.
• W2026522667 cites W1982109989 @default.
• W2026522667 cites W1986143238 @default.
• W2026522667 cites W1992337831 @default.
• W2026522667 cites W1996977215 @default.
• W2026522667 cites W2025619082 @default.
• W2026522667 cites W2028082582 @default.
• W2026522667 cites W2030052255 @default.
• W2026522667 cites W2037218885 @default.
• W2026522667 cites W2039602892 @default.
• W2026522667 cites W2040288000 @default.
• W2026522667 cites W2050383513 @default.
• W2026522667 cites W2057545376 @default.
• W2026522667 cites W2058769895 @default.
• W2026522667 cites W2066288167 @default.
• W2026522667 cites W2068873868 @default.
• W2026522667 cites W2074323366 @default.
• W2026522667 cites W2079675222 @default.
• W2026522667 cites W2126587119 @default.
• W2026522667 cites W4205215699 @default.
• W2026522667 cites W4293765665 @default.
• W2026522667 doi "https://doi.org/10.1177/00912700122010528" @default.
• W2026522667 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11402632" @default.
• W2026522667 hasPublicationYear "2001" @default.
• W2026522667 type Work @default.
• W2026522667 sameAs 2026522667 @default.
• W2026522667 citedByCount "247" @default.
• W2026522667 countsByYear W20265226672012 @default.
• W2026522667 countsByYear W20265226672013 @default.
• W2026522667 countsByYear W20265226672014 @default.
• W2026522667 countsByYear W20265226672015 @default.
• W2026522667 countsByYear W20265226672016 @default.
• W2026522667 countsByYear W20265226672017 @default.
• W2026522667 countsByYear W20265226672018 @default.
• W2026522667 countsByYear W20265226672019 @default.
• W2026522667 countsByYear W20265226672020 @default.
• W2026522667 countsByYear W20265226672021 @default.
• W2026522667 countsByYear W20265226672022 @default.
• W2026522667 countsByYear W20265226672023 @default.
• W2026522667 crossrefType "journal-article" @default.
• W2026522667 hasAuthorship W2026522667A5037226126 @default.
• W2026522667 hasAuthorship W2026522667A5049912941 @default.
• W2026522667 hasAuthorship W2026522667A5084392741 @default.
• W2026522667 hasConcept C126894567 @default.
• W2026522667 hasConcept C142724271 @default.
• W2026522667 hasConcept C197934379 @default.
• W2026522667 hasConcept C204787440 @default.
• W2026522667 hasConcept C27081682 @default.
• W2026522667 hasConcept C2777844464 @default.
• W2026522667 hasConcept C2778375690 @default.
• W2026522667 hasConcept C2778689640 @default.
• W2026522667 hasConcept C2778941218 @default.
• W2026522667 hasConcept C2781020410 @default.
• W2026522667 hasConcept C42219234 @default.
• W2026522667 hasConcept C71924100 @default.
• W2026522667 hasConcept C98274493 @default.
• W2026522667 hasConceptScore W2026522667C126894567 @default.
• W2026522667 hasConceptScore W2026522667C142724271 @default.
• W2026522667 hasConceptScore W2026522667C197934379 @default.
• W2026522667 hasConceptScore W2026522667C204787440 @default.
• W2026522667 hasConceptScore W2026522667C27081682 @default.
• W2026522667 hasConceptScore W2026522667C2777844464 @default.
• W2026522667 hasConceptScore W2026522667C2778375690 @default.
• W2026522667 hasConceptScore W2026522667C2778689640 @default.
• W2026522667 hasConceptScore W2026522667C2778941218 @default.
• W2026522667 hasConceptScore W2026522667C2781020410 @default.
• W2026522667 hasConceptScore W2026522667C42219234 @default.
• W2026522667 hasConceptScore W2026522667C71924100 @default.
• W2026522667 hasConceptScore W2026522667C98274493 @default.
• W2026522667 hasIssue "6" @default.
• W2026522667 hasLocation W20265226671 @default.
• W2026522667 hasLocation W20265226672 @default.
• W2026522667 hasOpenAccess W2026522667 @default.
• W2026522667 hasPrimaryLocation W20265226671 @default.
• W2026522667 hasRelatedWork W1504077734 @default.
• W2026522667 hasRelatedWork W1542102176 @default.
• W2026522667 hasRelatedWork W1821426726 @default.
• W2026522667 hasRelatedWork W2056717611 @default.
• W2026522667 hasRelatedWork W2058646317 @default.
• W2026522667 hasRelatedWork W2079785628 @default.
• W2026522667 hasRelatedWork W2081386520 @default.
• W2026522667 hasRelatedWork W2081806057 @default.
• W2026522667 hasRelatedWork W2406257615 @default.
• W2026522667 hasRelatedWork W3155740987 @default.
• W2026522667 hasVolume "41" @default.
• W2026522667 isParatext "false" @default.
• W2026522667 isRetracted "false" @default.
• W2026522667 magId "2026522667" @default.
• W2026522667 workType "article" @default.